Monday morning, specialty pharmaceutical company Jazz Pharmaceuticals, Inc. (JAZZ) said Nathaniel Zilkha has been elected to the company's Board of Directors, effective October 4. The company also announced resignation of Adam Clammer from its Board of Directors effective October 3.
The Palo Alto, California headquartered company said Zilkha is a Principal at Kohlberg Kravis Roberts & Co. L.P., where he is a member of the Health Care industry team. Prior to joining KKR earlier this year, he was a Vice President in the Principal Investment Area of Goldman Sachs, where he executed and monitored private equity investments on behalf of the GS Capital Partners family of funds and led the group's efforts in Healthcare and Life Sciences.
JAZZ is currently down $0.26 or 1.93% and trades at $13.24.
For comments and feedback: editorial@rttnews.com